Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
about
Correlates of Protection for M Protein-Based Vaccines against Group A StreptococcusImportance of circulating antibodies in protection against meningococcal diseaseGroup B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countriesImmunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trialCorrelation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activityPersistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.Recent Progress in the Prevention of Serogroup B Meningococcal Disease.Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in UgandaThe influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease.Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccineKinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccSerum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiencySerologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagersUpdated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityEvaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine.Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteriaIs a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixedPersistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccineIdentifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccineMeningococcal glycoconjugate vaccines.Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia.Meningococcal conjugate vaccines: optimizing global impact.Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.Some extensions in continuous models for immunological correlates of protection.Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America.Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges.Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.A universal vaccine for serogroup B meningococcus
P2860
Q27009175-FD0224D6-022C-4C81-B50C-0C25B06C4D74Q27023516-E2BE97B0-2282-4DB2-BB4C-C1B30E7D8C3CQ28075884-9D67FC7B-90B0-43AF-90AF-4F92CECA9354Q28650557-D2795611-457A-40E7-8FEC-A554EC35DEB4Q28732187-B361EC63-D638-48F9-8794-7261F6B66B97Q30210120-AA08CDFF-BB31-4D6F-A638-7D303AC14000Q30235040-56725C54-493D-4C16-B7B0-AEB3FFEAC4C1Q33388680-8737936C-BE10-4333-90FA-19267D272893Q33535924-6580C8D9-D2A0-4EDE-B1F2-F2CA84314CE2Q33600936-2A8F921B-6909-45BE-8C18-7956D8D304F9Q33613482-8B3083D1-2E8B-4ECB-BE09-0B700E08A026Q33768741-BC94A979-62CD-438E-8155-9414996EFA5DQ33769150-9A37A18F-6533-4E1C-9F00-CCCB5B0B4440Q33806774-A830CB80-B05A-441F-AD18-1EE21C7D36ADQ33825722-9B5C4E92-1668-4401-8F38-6DFC63FCC0E9Q33895627-A7FA21AC-8E49-4D91-AD62-B25693B44976Q33910760-778A138B-0582-4F43-BBF5-9AAE6A5785DDQ33939014-EF3CC9D5-79AE-480B-8A92-B74AF2E3A05CQ33959308-D296F512-6A2C-449B-AFC3-FB108D1595DCQ34145007-BF260C64-D914-4495-A0CC-B128EB7EFB26Q34153704-8940DE38-4FCD-4629-B9C5-D89927D1D492Q34194667-24D73E20-37F6-4DC0-BC2C-1DB00A392A22Q34480575-35FF4F8E-630A-4C5B-841A-F993F096D6ADQ34721179-52B14FB1-6189-4581-85A8-EB17A4466CCAQ34738958-80B1D2F1-72DB-4B02-8114-5C6D5AAA33DEQ34975007-D34A80F7-B07F-4D01-A6C7-8C1BD22F987BQ35066182-77DDFE42-D21A-4FD7-8B12-5A346B222AC9Q35194824-DCC93711-DFA6-43F3-B0AC-36E49E07D98CQ35217627-16BC65AE-AC98-4A6F-9418-71209726FF8FQ35542416-679DAE46-A33D-4AE7-9A64-1FBD4075B2B6Q35547767-2B1139A2-B4FE-47A8-9819-D17DFE0E35AAQ35598188-6FDE165F-0727-49DE-9FDD-78256DF6472EQ35783511-BF3C1839-2A0E-434D-84A6-96C5C18CF2B9Q35783606-261F7A36-1542-4F8E-A4F1-68D9CBD2A1F5Q35878996-36EBF00C-9F29-4299-B681-7DF93431BDE1Q35880805-ECED2D54-C0A6-4CA9-A733-D4D22F86E63BQ35886464-7AB0F583-93EE-44F8-8A57-07EFC6E1DEC2Q35887266-352AA3B6-EF16-4F09-AF0B-94FA34F30B56Q36045855-AFD12632-DBDB-4922-B3AB-16404D132EC1Q36101910-4795D7E9-2F8A-405F-AEA2-B76E3824FEFC
P2860
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Validation of serological corr ...... ensure surveillance in England
@ast
Validation of serological corr ...... ensure surveillance in England
@en
type
label
Validation of serological corr ...... ensure surveillance in England
@ast
Validation of serological corr ...... ensure surveillance in England
@en
prefLabel
Validation of serological corr ...... ensure surveillance in England
@ast
Validation of serological corr ...... ensure surveillance in England
@en
P2860
P1476
Validation of serological corr ...... ensure surveillance in England
@en
P2093
Elizabeth Miller
Nick Andrews
P2860
P304
P356
10.1128/CDLI.10.5.780-786.2003
P50
P577
2003-09-01T00:00:00Z